Open AccessWill controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?
Author(s) -
Debasis Chakraborty,
Avijit Hazra,
Abheek Sil,
Shantasil Pain
Publication year - 2019
Publication title -
journal of family medicine and primary care
Language(s) - English
Resource type - Journals
eISSN - 2278-7135
pISSN - 2249-4863
DOI - 10.4103/jfmpc.jfmpc_522_19
Subject(s) - medicine , irritable bowel syndrome , placebo , randomized controlled trial , adverse effect , abdominal pain , placebo controlled study , quality of life (healthcare) , gastroenterology , traditional medicine , physical therapy , double blind , alternative medicine , nursing , pathology
Irritable bowel syndrome (IBS) is a chronic relapsing disorder characterized by abdominal pain-discomfort and altered bowel habits. The IBS-diarrhoea predominant subtype (IBS-D) is defined as >25% of bowel movements representing type 6 or 7 of the Bristol Stool Form Scale. Management of IBS-D is mainly symptomatic, including lifestyle modification. Due to absence of standard treatment, multiple drugs are used. A controlled release (CR) form of mebeverine, recommended for spasmodic gastrointestinal disorders (including IBS) has recently been introduced in Indian market. We have conducted a placebo-controlled double blind randomized controlled trial [CTRI/2018/03/012897] to evaluate the effectiveness and safety of this product.